Blood Biomarkers for Uveal Melanoma

Triozzi, Pierre L.; Singh, Arun D.

doi:10.2217/fon.11.150

Cited by 10 publications

(5 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Obtaining uveal melanoma tumors for genotyping can be problematic. There is a need for blood biomarkers [ 10 ]. miRs are very stable in blood due in part to their incorporation into microparticles and exosomes, and serum and plasma levels of miRs are also under investigation as diagnostic and prognostic biomarkers in cancer and other diseases [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Association of tumor and plasma microRNA expression with tumor monosomy-3 in patients with uveal melanoma

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Association of tumor and plasma microRNA expression with tumor monosomy-3 in patients with uveal melanoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…With availability of highly accurate prognostication tests 11,12 for uveal melanoma and the trend toward adjuvant therapy, 28,29 systemic staging for metastasis at baseline followed by periodic surveillance for metastasis will increasingly become an important component of the overall management strategy that may be tailored to a patient's prognostic status and the adjuvant therapy that he or she might be receiving. [29][30][31]…”

Section: Discussionmentioning

confidence: 99%

Hepatic Ultrasonography for Surveillance in Patients With Uveal Melanoma

et al. 2016

View full text Add to dashboard Cite

IMPORTANCE There is a lack of information regarding the role of systemic surveillance in patients with primary uveal melanoma. OBJECTIVE To evaluate the utility of serial hepatic ultrasonography (USG) for detection of asymptomatic liver metastases in patients undergoing surveillance after primary treatment of uveal melanoma. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study reviewing data from patients with primary uveal melanoma treated between October 2003 and October 2012 at a multispecialty tertiary care center. Patients were managed using a standardized protocol. Initial staging was done with contrast-enhanced computed tomography of the chest, abdomen, and pelvis. This was followed by periodic surveillance with hepatic USG and liver function tests scheduled every 6 months for the first 5 years and annually thereafter. Abnormal surveillance hepatic USG findings were categorized as (1) cyst or hemangioma, (2) indeterminate lesion, (3) suspicious for metastasis, or (4) consistent with metastasis. If indicated, hepatic USG abnormalities were confirmed by additional imaging modalities (confirmatory scans) such as computed tomography or magnetic resonance imaging. Liver biopsy was performed only if the confirmatory scan was positive. MAIN OUTCOMES AND MEASURES Sensitivity, specificity, and positive predictive value of hepatic USG for detecting asymptomatic liver metastases. RESULTS In 263 patients (121 men, 142 women; mean [SD] age at diagnosis, 61.1 [13.9] years), a total of 1390 hepatic USGs were performed, with a mean of 5.3 per patient (range, 1-17 per patient). Overall, 86 hepatic USGs of 71 patients (27%) were reported as abnormal. Of the 13 lesions identified as a cyst/hemangioma and 17 as indeterminate, 1 was found to be metastatic in each group (8% and 6%, respectively). Of 36 patients with findings suspicious for metastasis, 23 (64%) had metastasis confirmed. All 5 patients (100%) with findings consistent with metastasis had biopsy-proven metastasis. The sensitivity, specificity, and positive predictive value of hepatic USG for findings that were indeterminate or suspicious for metastasis were 96% (95% CI, 80%-99%), 88% (95% CI, 83%-91%), and 45% (95% CI, 33%-59%), respectively. Specificity of the confirmatory scan was greater than that of hepatic USG (93% [95% CI, 89%-96%] vs 88% [95% CI, 83%-91%], respectively; P < .001). Only 4 of 30 patients (13%) with metastasis had abnormal findings on simultaneous liver function tests. CONCLUSIONS AND RELEVANCE A stepwise surveillance protocol based on serial hepatic USGs followed by confirmatory scans offers high likelihood of detecting asymptomatic metastases in patients with primary uveal melanoma.

show abstract

“…This has determined that the most effective measure against this type of cancer is its early detection. As uveal melanoma tumours spread via the bloodstream, blood biomarkers may be useful to detect metastases early on and to monitor disease progression or the response to treatment (154).…”

Section: Blood Biomarkers For Uveal Melanomamentioning

confidence: 99%

Update on uveal melanoma: Translational research from biology to clinical practice (Review)

et al. 2020

View full text Add to dashboard Cite

Uveal melanoma is the most common type of intraocular cancer with a low mean annual incidence of 5-10 cases per million. Tumours are located in the choroid (90%), ciliary body (6%) or iris (4%) and of 85% are primary tumours. As in cutaneous melanoma, tumours arise in melanocytes; however, the characteristics of uveal melanoma differ, accounting for 3-5% of melanocytic cancers. Among the numerous risk factors are age, sex, genetic and phenotypic predisposition, the work environment and dermatological conditions. Management is usually multidisciplinary, including several specialists such as ophthalmologists, oncologists and maxillofacial surgeons, who participate in the diagnosis, treatment and complex follow-up of these patients, without excluding the management of the immense emotional burden. Clinically, uveal melanoma generates symptoms that depend as much on the affected ocular globe site as on the tumour size. The anatomopathological study of uveal melanoma has recently benefited from developments in molecular biology. In effect, disease classification or staging according to molecular profile is proving useful for the assessment of this type of tumour. Further, the improved knowledge of tumour biology is giving rise to a more targeted approach to diagnosis, prognosis and treatment development; for example, epigenetics driven by microRNAs as a target for disease control. In the present study, the main epidemiological, clinical, physiopathological and molecular features of this disease are reviewed, and the associations among all these factors are discussed. Contents 1. Introduction 2. Risk factors 3. Clinical manifestations 4. Anatomopathological study of uveal melanoma 5. Molecular classification of uveal melanoma: Genes involved 6. Uveal vs. cutaneous melanoma: Similarities and differences 7. Biology of uveal melanoma 8. Blood biomarkers for uveal melanoma 9. Proteomics and metabolomics in uveal melanoma 10. Clinical management of uveal melanoma 11. Conclusions and future directions

show abstract

Blood Biomarkers for Uveal Melanoma

Cited by 10 publications

References 86 publications

Association of tumor and plasma microRNA expression with tumor monosomy-3 in patients with uveal melanoma

Association of tumor and plasma microRNA expression with tumor monosomy-3 in patients with uveal melanoma

Hepatic Ultrasonography for Surveillance in Patients With Uveal Melanoma

Update on uveal melanoma: Translational research from biology to clinical practice (Review)

Contact Info

Product

Resources

About